Overcoming problems with adherence to osteoporosis medication

References

• Reginster JY, Lecart MP. Treatment of osteoporosis with bisphosphonates – do compliance and persistence matter? Bus. Brief Long-Term Healthcare5, 65–68 (2004).
   Google Scholar
• Burrell A, Wong P, Ollendorf D et al. Defining compliance, adherence and persistence: ISPOR Special Interest Working Group. Value Health8, A194–A195 (2005).
   Web of Science ®Google Scholar
• Lekkerkerker F, Kanis JA, Alsayed N et al. Group for the Respect of Ethics and Excellence in Science (GREES). Adherence to treatment of osteoporosis: a need for study. Osteoporos. Int.18, 1311–1317 (2007).
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet348, 1535–1541 (1996).
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA282, 1344–1352 (1999).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int.11, 83–91 (2000).
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD et al. Effects of risedronate on the risk of hip fracture in elderly women. Hip Interventiopn Program Study Group. N. Engl. J. Med.344, 333–340 (2001).
   PubMed Web of Science ®Google Scholar
• Chesnut CH 3rd, Skag A, Christiansen C et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Bone Miner. Res.19, 1241–1249 (2004).
   PubMed Web of Science ®Google Scholar
• Kothawala P, Badamgarav E, Ryu S, Miller R, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin. Proc.82, 1493–1501 (2007).
   PubMed Web of Science ®Google Scholar
• Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin. Pharmacother.10, 2303–2315 (2009).
   PubMed Web of Science ®Google Scholar
• Siris E, Selby P, Saag K, Borgström F, Herings R, Silverman S. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am. J. Med.122, S3–S13 (2009).
   PubMed Web of Science ®Google Scholar
• Blouin J, Dragomir A, Ste-Marie LG, Fernandes JC, Perreault S. Discontinuation of antiresorptive therapies: a comparison between 1998–2001 and 2002–2004 among osteoporotic women. J. Clin. Endocrinol. Metab.92, 887–894 (2007).
   PubMed Web of Science ®Google Scholar
• Brookhart MA, Avorn J, Katz JN et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am. J. Med.120, 251–256 (2007).
   PubMed Web of Science ®Google Scholar
• Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos. Int.17, 922–928 (2006).
   PubMed Web of Science ®Google Scholar
• Kendler D, Kung AW, Fuleihan G et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas48, 243–251 (2004).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Rabenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin. Interv. Aging1, 415–423 (2006).
   PubMed Web of Science ®Google Scholar
• Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin. Ther.24, 1871–1886 (2002).
   PubMed Web of Science ®Google Scholar
• Baroutsou B, Babiolakis D, Stamatiadou AE et al. Patient compliance and preference of alendronate once weekly administration in comparison with daily regimens for osteoporotic postmenopausal women. Ann. Rheum. Dis.63(Suppl. 1), 455 (2004).
   Google Scholar
• Weiss M, Vered I, Foldes AJ, Cohen YC, Shamir-Elron Y, Ish-Shalom S. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin. Exp. Res.17, 143–149 (2005).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr. Med. Res. Opin.21, 1453–1460 (2005).
   PubMed Web of Science ®Google Scholar
• Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin. Proc.80, 856–861 (2005).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin. Ther.28, 1686–1694 (2006).
   PubMed Web of Science ®Google Scholar
• Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr. Pract.12, 522–528 (2006).
   PubMedGoogle Scholar
• Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr. Med. Res. Opin.22, 2383–2391 (2006).
   PubMed Web of Science ®Google Scholar
• Weiss TW, McHorney CA. Osteoporosis medication profile preference: results from the PREFER-US study. Health Expect.10, 211–223 (2007).
   PubMed Web of Science ®Google Scholar
• Weiss TW, Gold DT, Silverman SL, McHorney CA. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr. Med. Res. Opin.22, 949–960 (2006).
   PubMed Web of Science ®Google Scholar
• Duarte JW, Bolge SC, Sen SS. An evaluation of patients’ preferences for osteoporosis medications and their attributes: the PREFER-International study. Clin. Ther.29, 488–503 (2007).
   PubMedGoogle Scholar
• Richards JB, Cherkas LF, Spector TD. An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults. Curr. Med. Res. Opin.23, 293–299 (2007).
   PubMed Web of Science ®Google Scholar
• Keen R, Jodar E, Iolascon G et al. European women’s preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Curr. Med. Res. Opin.22, 2375–2381 (2006).
   PubMed Web of Science ®Google Scholar
• Emkey R, Koltun W, Beusterien K et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr. Med. Res. Opin.21, 1895–1903 (2005).
   PubMed Web of Science ®Google Scholar
• Hadji P, Benhamou CL, Devas V et al. Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: results of BALTO II. Osteoporos. Int.17(Suppl. 1), S69 (2006).
   Google Scholar
• Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos. Int.21, 145–155 (2010).
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Babbitt AM, Piziak VK et al. Adherence to and gastrointestinal tolerability of monthly oral and quarterly intravenous ibandronate in women with previous intolerance in oral bisphosphonates: a 12-month, open-label prospective evaluation. Clin. Ther.30, 605–621 (2008).
   PubMed Web of Science ®Google Scholar
• McClung M, Recker R, Miller P et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone41, 122–128 (2007).
   PubMed Web of Science ®Google Scholar
• Saag K, Lindsay R, Kriegman A et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone40, 1238–1243 (2007).
   PubMed Web of Science ®Google Scholar
• Carnevale V, Nieddu L, Romagnoli E et al. Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. Osteoporos. Int.17, 478–483 (2006).
   PubMed Web of Science ®Google Scholar
• Petrella RJ, Jones TJ. Do patients receive recommended treatment of osteoporosis following hip fracture in primary care? BMC Fam. Pract.7, 31 (2006).
   PubMedGoogle Scholar
• Rabenda V, Vanoverloop J, Fabri V et al. Low incidence of anti-osteoporosis treatment after hip fracture. J. Bone Joint Surg. Am.90, 2142–2148 (2008).
   PubMed Web of Science ®Google Scholar
• Tosteson AN, Grove MR, Hammond CS et al. Early discontinuation of treatment for osteoporosis. Am. J. Med.115, 209–216 (2003).
   PubMed Web of Science ®Google Scholar
• Rossini M, Bianchi G, Di Munno O et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos. Int.17, 914–921 (2006).
   PubMed Web of Science ®Google Scholar
• Blouin J, Dragomir A, Moride Y et al. Impact of non-compliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br. J. Clin. Pharmacol.66, 117–127 (2008).
   PubMed Web of Science ®Google Scholar
• Grant AM, Avenell A, Campbell MK et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet365, 1621–1628 (2005).
   PubMed Web of Science ®Google Scholar
• Jackson RD, LaCroix AZ, Gass M et al. Women’s Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med.354, 669–683 (2006).
   PubMed Web of Science ®Google Scholar
• Antoniucci DM, Vittinghoff E, Palermo L, Black DM, Sellmeyer DE. Vitamin D insufficiency does not affect response of bone mineral density to alendronate. Osteoporos. Int.20, 1259–1266 (2009).
   PubMedGoogle Scholar
• Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos. Int.17, 1626–1629 (2006).
   PubMed Web of Science ®Google Scholar
• Ziller V, Zimmermann SP, Kalder M et al. Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr. Med. Res. Opin.26, 675–681 (2010).
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. Denosumab update. Curr. Opin. Rheumatol.21, 369–373 (2009).
   PubMedGoogle Scholar
• Kendler DL, Bessette L, Hill CD et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos. Int.21, 837–846 (2010).
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab.90, 2816–2822 (2005).
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med.350, 459–468 (2004).
   PubMed Web of Science ®Google Scholar
• Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Adv. Ther.25, 1235–1256 (2008).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Bruyere O, Sawicki A et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone45, 1059–1064 (2009).
   PubMed Web of Science ®Google Scholar
• Rabenda V, Reginster JY. Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporos. Int.21(12), 1993–2002 (2010).
   PubMedGoogle Scholar
• Breart G, Audran M, Brandi ML et al. Good safety and persistence of strontium ranelate in a prospective observational cohort study. Osteoporos. Int.20(Suppl. 1), S94 (2009) (Abstract P273).
   Google Scholar
• Yood RA, Emani S, Reed JI et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos. Int.14, 965–968 (2003).
   PubMed Web of Science ®Google Scholar
• Sebaldt RJ, Shane LG, Pham B et al. Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis treated in tertiary specialist care. J. Bone Miner. Res.19(Suppl. 1), S445 (2004).
   Google Scholar
• Eastell R, Garnero P, Vrijens B et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif. Tissue Int.72, 408 (2003).
   Google Scholar
• Rabenda V, Mertens R, Fabri V et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos. Int.19, 811–818 (2008).
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos. Int.19, 511–517 (2008).
   PubMed Web of Science ®Google Scholar
• van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr. Med. Res. Opin.22, 1757–1764 (2006).
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin. Proc.81, 1013–1022 (2006).
   PubMed Web of Science ®Google Scholar
• Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos. Int.18, 271–277 (2007).
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Andrade SE, Yood RA, Kahler KH. Consequences of poor compliance with bisphosphonates. Bone41, 882–887 (2007).
   PubMed Web of Science ®Google Scholar
• Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos. Int.21(11), 1943–1951 (2009).
   PubMedGoogle Scholar
• Wilkes MM, Navickis RJ, Chan WW, Lewiecki EM. Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos. Int.21, 679–688 (2010).
   PubMed Web of Science ®Google Scholar
• Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet370, 657–666 (2007).
   PubMed Web of Science ®Google Scholar
• Reginster JY. Calcium and vitamin D for osteoporotic fracture risk. Lancet370, 632–633 (2007).
   PubMedGoogle Scholar
• Bronder E, Klimpel A. Unused drugs returned to the pharmacy – new data. Int. J. Clin. Pharmacol. Ther.39, 480–483 (2001).
   PubMedGoogle Scholar
• Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch. Intern. Med.150, 841–845 (1990).
   PubMed Web of Science ®Google Scholar
• Berg JS, Dischler J, Wagner DJ et al. Medication compliance: a healthcare problem. Ann. Pharmacother.27(9 Suppl.), S1–S24 (1993).
   PubMed Web of Science ®Google Scholar
• McCombs JS, Thibaud P, McLaughlin-Miley C et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas48, 271–287 (2004).
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone38, 922–928 (2006).
   PubMed Web of Science ®Google Scholar
• Sullivan S, Kreling D, Hazlet TH. Non-compliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate. J. Res. Pharm. Econ.2, 19–33 (1990).
   Google Scholar
• Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am. J. Med.102, 43–49 (1997).
   PubMedGoogle Scholar
• Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos. Int.19, 1421–1429 (2008).
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY. Potential clinical and economic impact of nonadherence with osteoporosis medication. Calcif. Tissue Int.86, 202–210 (2010).
   Web of Science ®Google Scholar
• Sheehy O, Kindundu C, Barbeau M, LeLorier J. Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos. Int.20, 1583–1594 (2009).
   PubMed Web of Science ®Google Scholar
• Simpson SH, Eurich DT, Majumdar SR et al. A meta-analysis of the association between adherence to drug therapy and mortality. Br. Med. J.333, 15 (2006).
   PubMed Web of Science ®Google Scholar
• Ettinger B, Pressman AR, Schein J et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient’s instructions and discontinuation. J. Manag. Care Pharm.4, 488–492 (1998).
   Google Scholar
• Aki S, Eskiyurt N, Akarirmak U et al. Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. Yonsei Med. J.44, 961–967 (2003).
   PubMed Web of Science ®Google Scholar
• McHorney CA, Schousboe JT, Cline RR, Weiss TW. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr. Med. Res. Opin.23, 3137–3152 (2007).
   PubMed Web of Science ®Google Scholar
• Woo C, Gao G, Wade S, Hochberg MC. Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study. Curr. Med. Res. Opin..26, 1003–1009 (2010).
   PubMed Web of Science ®Google Scholar
• Miller NH. Compliance with treatment regimens in chronic symptomatic diseases. Am. J. Med.102, 43–49 (1997).
   PubMedGoogle Scholar
• Kennedy J, Teleu I, Mackay K. Unfilled prescriptions of Medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J. Manag. Care Pharm.14, 553–560 (2008).
   PubMed Web of Science ®Google Scholar
• Weiss TW, Henderson SC, McHorney CA, Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr. Med. Res. Opin.23, 2193–2203 (2007).
   PubMed Web of Science ®Google Scholar
• Solomon DH, Avorn J, Katz JN et al. Compliance with osteoporosis medications. Arch. Intern. Med.165, 2414–2419 (2005).
   PubMed Web of Science ®Google Scholar
• Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos. Int.17, 922–928 (2006).
   PubMed Web of Science ®Google Scholar
• Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos. Int.17, 1638–1644 (2006).
   PubMed Web of Science ®Google Scholar
• Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J. Gen. Intern. Med.23, 1815–1821 (2008).
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xi J, Westfall AO et al. Improving the prediction of medication compliance: the example of bisphoshponates for osteoporosis. Med. Care47, 334–341 (2009).
   PubMed Web of Science ®Google Scholar
• Gleeson T, Iversen MD, Avorn J et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos. Int.20, 2127–2134 (2009).
   PubMed Web of Science ®Google Scholar
• Cook PF, Emiliozzi S, McCabe MM. Telephone counselling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings. Am. J. Med. Qual.22, 445–456 (2007).
   PubMed Web of Science ®Google Scholar
• DiIorio C, McCarty F, Resnicow K et al. Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study. AIDS Care20, 273–283 (2008).
   PubMed Web of Science ®Google Scholar
• Golin CE, Earp J, Tien HC, Stewart P, Porter C, Howie L. A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART. J. Acquir. Immune Defic. Syndr.42, 42–51 (2006).
   PubMed Web of Science ®Google Scholar
• Schmaling KB, Blume AW, Afari N et al. A randomised controlled pilot study of motivational interviewing to change attitudes about adherence to medications for asthma. J. Clin. Psychol. Med. Settings8, 167–172 (2001).
   Web of Science ®Google Scholar
• Ogedegbe G, Chaplin W, Schoenthaler A et al. A practice-based trial of motivational interviewing and adherence in hypertensive African Americans. Am. J. Hypertens.21, 1137–1143 (2008).
   PubMed Web of Science ®Google Scholar
• McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA288, 2868–2879 (2002).
   PubMed Web of Science ®Google Scholar
• Belcon MC, Haynes RB, Tugwell P. A critical review of compliance studies in rheumatoid arthritis. Arthritis Rheum.27, 1227–1233 (1984).
   PubMed Web of Science ®Google Scholar
• Cuddihy MT, Amadio PC, Gabriel SE, Pankratz VS, Kurland RL, Melton LJ 3rd. A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture. Osteoporos. Int.15, 695–700 (2004).
   PubMed Web of Science ®Google Scholar
• Sedlak CA, Doheny MO, Jones SL. Osteoporosis education programs: changing knowledge and behaviors. Public Health Nurs.17, 398–402 (2000).
   PubMed Web of Science ®Google Scholar
• Estok PJ, Sedlak CA, Doheny MO, Hall R. Structural model for osteoporosis preventing behavior in postmenopausal women. Nurs. Res.56, 148–158 (2007).
   PubMed Web of Science ®Google Scholar
• Rolnick SJ, Kopher R, Jackson J, Fischer LR, Compo R. What is the impact of osteoporosis education and bone mineral density testing for postmenopausal women in a managed care setting? Menopause8, 141–148 (2001).
   PubMed Web of Science ®Google Scholar
• Guilera M, Fuentes M, Grifols M, Ferrer J, Badia X. Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporos. Int.17, 664–671 (2006).
   PubMedGoogle Scholar
• Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int. J. Clin. Pract.60, 896–905 (2006).
   PubMed Web of Science ®Google Scholar
• Briot K, Ravaud P, Dargent-Molina P, Zylberman M, Liu-Leage S, Roux C. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos. Int.20, 625–630 (2009).
   PubMed Web of Science ®Google Scholar
• Nielsen D, Ryg J, Nielsen W, Knold B, Nissen N, Brixen K. Patient education in groups increases knowledge of osteoporosis and adherence to treatment: a two-year randomized controlled trial. Patient Educ. Couns.81(2), 155–160 (2010).
   PubMed Web of Science ®Google Scholar
• Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J. Clin. Endocrinol. Metab.89, 1117–1123 (2004).
   PubMed Web of Science ®Google Scholar
• Delmas PD, Vrijns B, Roux C et al. Reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: the IMPACT study. J. Bone Miner. Res.18(Suppl. 2), S374 (2003).
   Google Scholar
• Rubin SM, Cummings SR. Results of bone densitometry affect women’s decision about taking measures to prevent fractures. Ann. Intern. Med.116, 990–995 (1992).
   PubMed Web of Science ®Google Scholar
• Yasin S. Detecting and improving compliance: is concordance the solution? Aust. Fam. Physician27, 255–260 (1998).
   PubMedGoogle Scholar
• Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging21, 793–811 (2004).
   PubMed Web of Science ®Google Scholar
• Wilson SR, Strub P, Buist AS et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am. J. Respir. Crit. Care Med.181, 566–577 (2010).
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin. Ther.30, 605–621 (2008).
   PubMed Web of Science ®Google Scholar
• Faught E, Duh MS, Weiner JR et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study. Neurology71, 1572–1578 (2008).
   PubMed Web of Science ®Google Scholar
• Faught RE, weiner JR, Guerin A et al. Impact of nonadherence to antiepileptic drugs in healthcare utilization and costs: findings from the RANSOM study. Epilepsia50, 501–509 (2009).
   PubMed Web of Science ®Google Scholar
• Lage MJ, Hassan MK. The relationship between antipsychotic medicaton adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. Ann. Gen. Psychiatry8, 7 (2009).
   PubMedGoogle Scholar
• Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care43, 521–530 (2005).
   PubMed Web of Science ®Google Scholar
• Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am. J. Med.114, 39–43 (2003).
   PubMed Web of Science ®Google Scholar
• Ho PM, Spertus JA, Masoudi FA et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch. Intern. Med.166, 1842–1847 (2006).
   PubMed Web of Science ®Google Scholar
• Ho PM, Magid DJ, Shetterly SM et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am. Heart J.155, 772–779 (2008).
   PubMed Web of Science ®Google Scholar
• Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation117, 1028–1036 (2008).
   PubMed Web of Science ®Google Scholar
• Body JJ. Update on treatment of postmenopausal osteoporosis. Rev. Med. Brux.29, 301–309 (2008).
   PubMedGoogle Scholar
• Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H. Cost–effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr. Med. Res. Opin.23, 2517–2529 (2007).
   PubMed Web of Science ®Google Scholar
• Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am. J. Med.119, S25–S31 (2006).
   PubMed Web of Science ®Google Scholar
• Haynes RB, Yao X, Degani A et al. Interventions to enhance medication adherence. Cochrane Database Syst. Rev. (4), CD000011 (2005).
   Google Scholar
• Bosmans JE, Brook OH, van Hout HP et al. Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants. Pharmacoeconomics25, 25–37 (2007).
   PubMed Web of Science ®Google Scholar
• Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J. Clin. Hypertens.10, 348–354 (2008).
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xi J, Westfall AO et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med. Care47, 334–341 (2009).
   PubMed Web of Science ®Google Scholar
• Body JJ, Bergmann P, Boonen S et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos. Int.21(10), 1657–1680 (2010).
   PubMed Web of Science ®Google Scholar
• Andrade SE, Majumdar SR, Chan KA et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch. Intern. Med.163, 2052–2057 (2003).
   PubMed Web of Science ®Google Scholar
• Gardner MJ, Flik KR, Mooar P, Lane JM. Improvement in the undertreatment of osteoporosis following hip fracture. J. Bone Joint Surg. Am.84-A(8), 1342–1348 (2002).
   Google Scholar
• Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos. Int.15, 120–124 (2004).
   PubMed Web of Science ®Google Scholar
• Freedman KB, Kaplan FS, Bilker WB et al. Treatment of osteoporosis: are physicians missing an opportunity? J. Bone Joint Surg. Am.82-A(8), 1063–1070 (2000).
   Google Scholar